Showing results (11-20 of 1,827) with videos related to

Sort By:
Pageof 183
ESMO Open|August 28, 2020
Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspectsLuca Moscetti, Paula Hennik, Bjorg Bolstad, et al.
ESMO Open|August 28, 2020
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trialRobin Kate Kelley, Baek-Yeol Ryoo, Philippe Merle, et al.
ESMO Open|February 4, 2021
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor BoardsR Danesi, S Fogli, S Indraccolo, et al.
ESMO Open|February 8, 2021
BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancerDaisuke Kotani, Hideaki Bando, Hiroya Taniguchi, et al.
ESMO Open|January 3, 2022
Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patientsT Samaille, C Moreau Bachelard, E Coquan, et al.
ESMO Open|January 7, 2022
How we treat patients with metastatic HER2-positive breast cancerG Nader-Marta, D Martins-Branco, E de Azambuja
ESMO Open|January 1, 2022
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-upA Lasagna, D Lilleri, F Agustoni, et al.
ESMO Open|March 21, 2021
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7T Takahashi, K Yamazaki, E Oki, et al.
ESMO Open|December 24, 2021
Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunitiesM Simbolo, G Centonze, G Ali, et al.
ESMO Open|December 25, 2021
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancerO Molinier, B Besse, F Barlesi, et al.
Pageof 183